Assessment of a close respiratory follow-up schedule at 3 and 6 months after acute COVID-19 and its related investigations

Respir Med. 2023 Oct:217:107367. doi: 10.1016/j.rmed.2023.107367. Epub 2023 Jul 20.

Abstract

Background: Respiratory sequela after acute COVID-19 is common and requires medical follow-up. Considering its vast economic impact, there is still no consensus regarding the mid-term follow-up plan after recovery.

Objective: To evaluate the necessity of a close pulmonary follow-up schedule after acute COVID-19 and its related investigations.

Methods: A prospective cohort study including adult patients after acute COVID-19 pneumonia. Patients were invited or referred to a 3- and 6-month follow-up visits at a large pulmonary institute in a tertiary center. Before each visit, patients completed demographic and clinical questionnaires, pulmonary function tests (PFTs), and chest CT scans.

Results: 168 patients were included after completing both visits (medians of 80 and 177 days). Their mean age was 58 ± 15 and 52% recovered from severe or critical COVID-19. Between the two visits, there was no change in DLCOc (mean 73 ± 18 %predicted in both visits) and FVC (mean 90 ± 16 vs. 89 ± 16 %predicted). The COPD assessment tool and modified Medical Research Council scale had inverse correlations with the DLCOc, and similarly did not change between the visits. Occupational exposures were the only factor associated with a change in DLCOc during follow-up (3% decrease, p = 0.04). An improvement in chest CT findings at the second visit was not associated with a change in PFTs.

Conclusions: Most clinical variables did not change during a close follow-up schedule in the first six months after acute COVID-19. Such a follow-up plan does not appear necessary and should be personalized to limit excessive costs and resources.

Keywords: Dyspnea; Long-COVID; Monitoring; Pulmonary function tests; SARS-COV-2.

MeSH terms

  • Adult
  • Aged
  • COVID-19* / epidemiology
  • Follow-Up Studies
  • Humans
  • Lung
  • Middle Aged
  • Prospective Studies
  • SARS-CoV-2